Compare Recursion Pharmaceuticals Inc (RXRX) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Zillow Group Inc Class A — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while Zillow Group Inc Class A trades at $32.92 (market cap $7.26B). The key difference: Zillow Group Inc Class A is far larger — about 4.2× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| RXRX | ZG | |
|---|---|---|
Market Cap | $1.74B | $7.26B |
Sector | Health | Media |
52-Week High | $6.79 | $86.76 |
52-Week Low | $2.84 | $29.14 |
Enterprise Value | $1.26B | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
Zillow Group (ZG) trades at $33.03, down 6.48% over 24 hours, reflecting bearish technical signals amid a challenging housing market. The stock shows mixed fundamentals with a high P/E ratio of 143.57 but improving revenue growth to $2.58B in 2025 and a return to net profitability. Recent news highlights Zillow's shift to an integrated transaction platform and a settled FTC lawsuit, while analyst consensus remains cautiously optimistic with a $47.56 price target.
The outlook balances growth potential from Zillow's monetization strategy against near-term headwinds like elevated interest rates dampening home sales. Risks include execution challenges in the business model transition and competitive pressures, but institutional buying and earnings beats suggest underlying strength. Investors should weigh the high valuation against improving cash flow and market positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
